We report the proceedings of the First International new-onset refractory status epilepticus (NORSE) and febrile infection-related epilepsy syndrome (FIRES) Symposium. To promote awareness of this condition and foster research efforts, we conveyed the First International new-onset refractory status epilepticus (NORSE) and febrile infection-related epilepsy syndrome (FIRES) Symposium.
| INTRODUCTION
The cause of status epilepticus (SE) is often easily identified with a standardized approach. 1 A careful history taking, neurological examination, and basic laboratory tests might identify the most common etiologies of SE, such as nonadherence or changes in antiseizure treatment, intoxication, central nervous system (CNS) infections, acute or remote structural brain injury, acute metabolic imbalances, and alcohol withdrawal. 2 In up to 20% of cases, however, this initial work-up may be unrevealing, and the clinician is left with the difficulty of pinpointing one of the many uncommon causes of SE. 3, 4 In the management of acute seizures and SE, we invariably prioritize the control of seizures over the determination and treatment of the underlying cause. However, finding the etiology of SE has both therapeutic and prognostic implications, perhaps even more importantly when dealing with refractory SE. Diagnostic and therapeutic delay contributes to poor outcome in a variety of diseases that can cause SE, 5 and seizure control might only be achieved provided the underlying cause is known and treated. With close to 200 uncommon disorders that can cause SE, 3 there is a need to define this clinical situation and to develop guidelines for a rational and efficient workup. In a small but nonnegligible group of patients-mostly previously healthy young adults and children-an extensive diagnostic workup fails to reveal the cause of SE. This group may represent up to 60% of cases of de novo refractory SE. 2, 6 It is often misclassified as "possible encephalitis" in epidemiological studies, as diagnostic criteria for autoimmune and infectious encephalitis do not require the formal identification of the causative antibody or pathogen. 7, 8 Prolonged seizure activity can cloud consciousness and alter cognition, and cause focal neurological deficits, as well transient magnetic resonance imaging (MRI) and cerebrospinal fluid (CSF) changes, [9] [10] [11] 20 The rest of this article summarizes the other discussions that were held at the First International NORSE and FIRES Symposium following the smaller, invitation-only consensus definition conference. The first part describes recent developments in the description and pathophysiology of NORSE and FIRES. The second part presents ongoing efforts to improve public advocacy, clinical research, and care of patients with these uncommon but devastating infections.
| NORSE IN ADULTS AND FIRES IN CHILDREN: SIMILAR OR DIFFERENT CONDITIONS
By consistently using the terms NORSE and FIRES in different age groups (adults and children, respectively), the existing literature suggests that they represent different conditions. Beyond the age distinction, available case series provide data pointing to 2 other possible differences between the 2 disorders. First, a preceding fever is the rule with FIRES, 16 whereas it is absent in one-third of NORSE cases. 14 It is possible, however, that this dissimilarity could be due simply to reporting bias (the parents of a sick child are more likely to report symptoms than the sometimes distant relatives of a sick adult) or publication bias (fever is a prerequisite for FIRES-even if not always clearly reported -while it is not necessary for NORSE). These differences between NORSE and FIRES seem to be in large part due to the use of arbitrary criteria (age groups, presence of a preceding documented febrile illness) that are not backed up by solid scientific evidence and introduce selection and reporting bias. Second, although there is a male predominance in FIRES in children, NORSE in adults more often affects women. 14, 16 However, this does not exclude that FIRES and NORSE are the same condition, as changes in gender bias with age have been reported in other disorders. Furthermore, in many other key aspects, NORSE and FIRES appear largely similar. Both conditions occur in patients without a previous history of epilepsy and often present as a progressive build-up of seizures that evolve to prolonged refractory SE. Nonspecific CSF and imaging findings are found in both with a similar frequency, and cerebral biopsy, when available, does not provide any specific findings that can distinguish one condition from the other. 13 The outcome is similarly poor as well, with severe neurological sequelae, mortality in up to one-fifth of patients, and refractory epilepsy. Hence, there have been arguments in favor of reconciling the 2 syndromes. [21] [22] [23] By applying the same definition across the lifespan, we aim to facilitate inclusive research and comparison between different age groups. Further elucidation of the causes and natural history etiologies may permit further separation or merging of underlying conditions in the future.
| PATHOPHYSIOLOGICAL HYPOTHESIS: A GENETICALLY DETERMINED, POSTINFECTIOUS, CYTOKINE-MEDIATED DISORDER? (ANDREAS VAN BAALEN AND RIMA NABBOUT)
Cryptogenic NORSE and FIRES are characterized by the rapidly progressive onset of seizures and encephalopathy that evolve into prolonged superrefractory SE over a few days. In FIRES, this is preceded by a minor febrile infection. Unlike chronic epilepsy with explosive onset, the single episode of SE in NORSE and FIRES can last for weeks and, unlike encephalitis, drug-resistant epilepsy follows without a latent period. 19, 22 At first sight, cryptogenic NORSE and FIRES may appear to share some commonalities with well-described fever-sensitive epilepsy syndromes, such as Dravet syndrome, or with inborn errors of metabolism in which fever and infections may precipitate seizures, such as mitochondrial disorders. However, in cryptogenic NORSE and FIRES, SE often starts not during but after the febrile episode, and therefore after the main infectious and resulting metabolic stress. In addition, patients with cryptogenic NORSE and FIRES experience only 1 episode of SE. 19, 22 These observations argue against a metabolic disease or a fever-sensitive epilepsy syndrome. Furthermore, in a few tested cases, mutations were not found in the SCN1A, POLG1, and PCDH19 genes. 24 A unifying mechanism that could account for the all the specific features of cryptogenic NORSE and FIRES is still lacking. It is, however, tempting to speculate that it might be caused by a fulminant inflammatory response in the CNS. 25 An intrathecal overproduction of proinflammatory cytokines and chemokines has been described in children with FIRES, and was not observed in the CSF of controls with other inflammatory and noninflammatory neurological conditions. 26 Several of these molecules have proconvulsant activity. This accumulation could be the product of the activation of T cells, perivascular cells, and glia and could take several days, perhaps explaining the latency between the febrile episode and the onset of SE. However, it is currently unclear whether intrathecal inflammation is the cause or the consequence of the prolonged episode of refractory SE (RSE), as controls with RSE of noninflammatory origin were not studied. Furthermore, whether this cytokine storm is sufficient to explain a long-lasting severe episode of SE is also unclear, and additional mechanisms such as mitochondrial dysfunction or synaptic plasticity may occur. Individual predisposition may be determined by allelic variations in HLA subtypes or cytokine pathways, as in other postinfectious neurological disorders. 27, 28 Further studies to confirm these hypotheses are ongoing. Given the rarity of the disease and the complexity of the underlying mechanisms, further collaborative work, including a multinational clinical registry and biorepository and partnership with immunology and genetic research groups, is required to confirm these preliminary hypotheses.
| THE ROLE OF IMMUNE THERAPIES IN CRYPTOGENIC NORSE AND FIRES (NICOLA SPECCHIO)
There is currently no specific therapy for cryptogenic FIRES and NORSE, and conventional antiseizure medications show very limited success. 14, 16, 29 Continuous intravenous anesthetics, including barbiturates, can temporarily stop seizure activity in the acute phase, although seizures often recur as soon as they are discontinued, and there has been no evidence that long-term outcomes were improved. (Table 1) . [12] [13] [14] 16, 19, [30] [31] [32] [33] [34] [35] [36] [37] No randomized controlled trial is available, and data come from single case reports and small uncontrolled series, which are prone to report bias. There is currently no consensus regarding the use of immune therapies in NORSE, but they are nonetheless often used, including by some of the authors. Similar to autoimmune encephalitis, first-line immune therapies are the most commonly used but typically show a low response rate (Table 1) . Suggested dosages are presented in Table 1 . Too little information is available on the adequate dosage of other treatments to formulate any recommendation. The KD is an established treatment for drug-resistant epilepsy, with both anti-seizure and anti-inflammatory effects. In animal models, it is associated with a reduction of plasma levels of pro-inflammatory cytokines. 38 There have been reports of a dramatic response (approximately 50%) to KD in children with FIRES, but this needs to be confirmed in prospective controlled studies.
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Cannabidiol (CBD) is a recent potential alternative therapy in epilepsy and has been shown to improve seizure frequency and duration in the acute or chronic phase of infection in 6 of 7 reported patients with FIRES. 40 Anakinra is a recombinant version of human interleukin-1 (Il-1) receptor antagonist, which inhibits the biological actions of Il-1 beta. Increased expression of Il-1 beta in microglia and astrocytes is observed in in various forms of drug-resistant epilepsy. A single case has been reported of a 32-month-old girl with FIRES who received 5 mg/kg twice daily. 41 After 6 months of seizure freedom, weaning attempts to 1 daily dose were unsuccessful. The drug was well tolerated and effective, leading to a dramatic seizure reduction on 3 separate occasions in the same patient; however, no long-term follow-up is available. 42 Finally, therapeutic hypothermia exhibits neuroprotective and anti-inflammatory properties in vivo after perinatal asphyxia and adult cardiac arrest, by reducing proinflammatory cytokine levels and protecting the integrity of the blood-brain barrier. In 2 cases of FIRES, moderate therapeutic hypothermia at 33°C resulted in fast and sustained control of SE.
| THE QUEST FOR EARLY DIAGNOSTIC CLUES OF FIRES AND NORSE-A POSSIBLE ROLE FOR EEG (RAQUEL FARIAS-MOELLER)
The diagnosis of FIRES and NORSE is typically given late, if at all, in a patient's clinical course, which may hinder clinical care and research. The development of a specific diagnostic test for their early identification is needed. There is currently no available CSF or serological marker. Brain MRI may disclose suggestive findings, 43 but they are usually absent in the early phase and repeating imaging is not always practical. On the other hand, EEG can be performed early and continuously throughout the course of SE. In a retrospective analysis of children with FIRES, 3 commonalities were noted. 44 First, seizures were initially brief and relatively infrequent, with a gradual evolution to SE. Second, beta-delta complexes resembling extreme delta brush were observed. Finally, seizures had a characteristic electrographic pattern, typically beginning with prolonged focal fast activity, followed by the gradual appearance of well-formed rhythmic spike or spike-and-wave complexes. Shifting ictal activity was frequently observed. Whether or not these findings show any specificity to NORSE and FIRES is still unclear, and they deserve further study and confirmation, including in the adult NORSE population and in larger multicenter cohorts.
| CREATION OF A NORSE AND FIRES REGISTRY-THE ROLE OF PATIENTS' ORGANIZATION (JUDETTE LANCRENON, MICHEL EMMERY, RIMA NABBOUT, AND NICOLAS GASPARD)
The creation of a FIRES and NORSE registry poses several challenges. On the one hand, there is a need to collect indepth clinical details and to create a repository of biological samples. At the same time, FIRES and NORSE are relatively uncommon entities and a multicenter approach is required. The NORSE Institute is planning a prospective registry through 2 preexisting research networks, the CCEMRC and the Pediatric Status Epilepticus Research Group (pSERG; http://www.pserg.org), which together comprise over 50 academic medical institutions. The registry initially aims to enroll 100 consecutive patients with cryptogenic NORSE (including FIRES) over 2 years. It will collect clinical data, spanning from early critical care to long-term functional, cognitive and epilepsy outcome, as well as brain imaging, EEG, and biological samples (DNA, | 749 serum, CSF, and brain tissue, whenever available). Partnerships with genetic and immunological experts have been established. The registry will entail a heavy workload, limiting participation to a relatively small group of large medical centers. Data will be collected by clinicians during patient contacts, and long-term cognitive and quality-of-life endpoints will be investigated. The registry will also be restricted to a relatively narrow recruitment basis.
To address these limitations, the NORSE Institute is planning a family-and patient-based registry in partnership with the Paratonnerre association (http://associationpa ratonnerre.org). Paratonnerre is a European association supporting children affected by FIRES. Its objectives are the following: (1) to gather families and facilitate experience-sharing; (2) to inform about FIRES; (3) to represent persons affected by FIRES; and (4) to encourage scientific research. Created in 2012, it now comprises 160 individual members and 3 organizations (Fondation L'Or eal-Airbus staff council-Desautel), mobilized around 20 children affected by FIRES in France. The association is also in contact with 150 families worldwide. With the support of a scientific committee, Paratonnerre offers to coordinate a working group with patients, clinicians, and researchers interested in developing a patient-and family-oriented registry of individuals with NORSE and FIRES. Families and patients have a strong desire to better understand these syndromes and are thus eager to contribute to such a registry. On the other hand, doctors and researchers worldwide strive to increase scientific knowledge on these rare syndromes, usually with limited resources. Concerted action between all stakeholders is now critical to make such a registry exist. Coordination is indeed key to build on existing experiences and achievements, to make sure that the registry will match expectations and come as a user-friendly and accessible tool, based on the European Commission Expert Group on Rare Diseases (ECEGRD) core recommendations, as well as to facilitate fundraising for the registry itself and for subsequent research. Today, there seems to be a momentum: the creation of the EPICARE ERN (European Network of Reference for Rare Epilepsies) and the collaboration with the NORSE Institute coincide to make the development of the NORSE and FIRES registry more attainable than ever.
| COMMUNICATING ABOUT NORSE AND FIRES (NORA WONG)
Although we attempt to unravel the causes of NORSE and FIRES and improve patient care, we must build better ways to communicate with colleagues, patients, and families. Communication about NORSE is often delayed and incomplete because it is a diagnosis of exclusion and there are yet few empirical data. More effective communication must begin at the doctor level. Doctors should share information across institutions and areas of expertise. Because NORSE and FIRES are so uncommon, each specialist has treated only a limited number of patients. Sharing knowledge by participating in meetings, inviting outside specialists, and fostering multidisciplinary communication and collaboration is vital.
Doctors should also communicate fully with other medical teams within the hospital. This seems obvious, but the crisis environment and the rotation schedules of the medical teams make it difficult. Doctors can hold regular, interdisciplinary programs within their hospitals to discuss the multifaceted challenges of diagnosing and treating NORSE and other disorders with the same level of complexity and uncertainty. Doctors should hold ongoing, candid medical conferences with the family. General recommendations about physician-family interactions apply. 45 The team should designate case leaders to coordinate and integrate patient care and communication. The team itself should include members of the intensive care unit (ICU) and epilepsy teams, as well as nurses, social workers, and palliative care specialists. Conferences should be held periodically because the families will not be able to comprehend and accept all the information at once. Moreover, the patient's condition may change significantly over time.
Conferences should be held in a quiet, private room. During conversations, doctors should discuss the working diagnosis and the prognosis, using layman's language and openly acknowledging the uncertainty of the diagnosis and prognosis, discuss the treatment plan as well as the alternatives, outline the trajectory of the infection while still in the hospital, and well before discharge, outline what families might expect when they leave the hospital. It should never be assumed that someone else on the team has already informed the family. Some doctors may be reluctant to adopt this depth of communication because it is time-consuming and uncomfortable. But as uncomfortable as these discussions are, there are greater burdens that result from silence. Obviously, families bear the greatest burden. Families need time to prepare themselves for death or to begin a new life with their loved ones who most likely will be very different from whom they were before. Families need to know the name of the disorder. Just as scientists need consensus definitions around which to organize their thinking and research, families need to know what hurt their loved ones. Without a name, there is no closure. Knowing the name of the disorder allows families to find a community in which to share their grief, pool their knowledge, and to direct their actions and their resources. It is the community of patients and families that will participate in medical registries. It is the community of families that will fund research. Professionals and families can find NORSE information at www.norseinstitute.org. There is a final burden in NORSE. As technology advances and the boundaries of life and death blur, as life becomes measured by and dependent upon machines, value judgments are critical. Deciding whether further treatment is in the best interest of the patient can only be done after doctors and families communicate fully and honestly. This burden of responsibility should not be borne by the doctors alone, nor should it be thrust upon uninformed families.
| CONCLUSIONS
NORSE and FIRES are uncommon but difficult clinical situations. Little is known of their etiology, course, and treatment. By adopting a standardized terminology with operational definitions; joining efforts to reinforce registries, data collection, and biobanks; building a multidisciplinary multicenter research strategy; and improving communication on these disorders, we can hope to unravel their cause and improve patient care.
